Phenylketonurias Clinical Trial
— ESSENTIALOfficial title:
An Open-label, Explorative, Post Launch, Multicenter, Multi-country Intervention Study of PKU Synergy (an Amino-acid Mixture) to Evaluate Change in Nutrient Intake in PKU Subjects With an Increased Phe-tolerance/Intake
NCT number | NCT03777826 |
Other study ID # | MPR16TA09791 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 26, 2019 |
Est. completion date | May 27, 2021 |
Verified date | December 2021 |
Source | Nutricia Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phenylketonuria (PKU) is a rare inherited metabolic disorder, where subjects are born with a genetic deficiency in the phenylalanine hydroxylase enzyme (PAH), which leaves them unable to convert Phenylalanine (Phe) into Tyrosine (Tyr). Patients with mild PKU or partly responsive to the drug synthetic tetrahydrobiopterin (BH4) (Kuvan®) can change to a more relaxed diet. However due to difficulty to adapt their diet, these patients are at risk of an imbalanced nutritional status and an insufficient intake of specific micronutrients, essential amino acids and DHA (Docosahexaenoic acid). The study product is designed to improve the nutritional status of the patients. The study investigates if the nutritional status is indeed improved following 24 week use of the study product, and also the study aims to evaluate product acceptability.
Status | Completed |
Enrollment | 13 |
Est. completion date | May 27, 2021 |
Est. primary completion date | May 27, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion criteria: 1. PKU subjects identified by newborn screening and started low-Phe diet before 3 months of age 2. PKU subjects (with or without current AAM use) with an increased Phe-tolerance/intake due to: - Mild PKU phenotype - BH4 treatment 3. If treated with BH4, PKU subjects should be on a stable BH4 treatment for at least 26 consecutive weeks up to start test product intake 4. Age=12 years 5. If subjects (irrespective whether BH4 users or mild PKU) use amino-acid mixture(s; AAM), then a maximum of 25 Protein Equivalents (PE) derived from the AAM per day applies and usage on a daily basis for at least 26 consecutive weeks up to Visit 1 6. If subjects (irrespective whether BH4 users or mild PKU) use AAMs they should be capable and willing to substitute their current AAM(s; maximum of 25 PE per day) with one portion of the test product per day 7. If subjects (irrespective whether BH4 users or mild PKU) use omega-3, antioxidant, and/or vitamin supplements, to stop usage of the supplements and be able and willing to substitute with the test product 8. Willing and able to comply with study procedures 9. Willing and able to provide informed consent (and assent in case of minors if required by local law/regulations) 10. For women of childbearing potential: not to have the intention to become pregnant during the study Exclusion Criteria: 1. For women: Currently pregnant or lactating 2. Current or prior use of the test product within six weeks prior to entry into the study 3. Concurrent conditions (including renal failure and severe hepatic failure) and medication that could interfere with participation, outcome parameters or safety (as determined by Investigator) 4. Psychotropic medication (i.e. medication affecting the nervous system) and inotropic medication 5. Any condition creating high risk of poor compliance with study 6. Participation in any other studies involving investigational or marketed products concomitantly or within six weeks prior to entry into the study. Except for studies related to Kuvan® (synthetic tetrahydrobiopterin (BH4)) without diagnostic, therapeutic or experimental intervention. |
Country | Name | City | State |
---|---|---|---|
Germany | University hospital Leipzig | Leipzig | |
Germany | University hospital Münster | Münster | |
Netherlands | University Medical Center Groningen (UMCG) | Groningen |
Lead Sponsor | Collaborator |
---|---|
Nutricia Research |
Germany, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety Parameters (Incidence, frequency, seriousness, severity and relatedness of (Serious) Adverse Events) | Incidence, frequency, seriousness, severity and relatedness of (Serious) Adverse Events | 24 weeks | |
Other | Tolerance (Standard gastrointestinal questionnaire reporting) | Tolerance: Standard gastrointestinal questionnaire reporting of diarrhea constipation, abdominal distension, nausea, vomiting, burping, flatulence, regurgitation, and colic/cramps (0, 1, 12 and 24 weeks) [absent, mild, moderate, severe] | 24 weeks | |
Other | Subject characteristics | Age [years] Sex [male/female] Country [Germany/Netherlands] |
week 0 | |
Other | Phe tolerance level and/or range | [mg Phe/day] | week 0 | |
Other | PKU phenotype | Recording of PKU (Phenylketonuria) genotype from medical history [hyperphenylalaninemia (HPA) or mild/moderate/classic PKU] | week 0 | |
Primary | Nutrient intake | Change in nutrient intake after 24 weeks by analysis of 3 day diet diary. Nutrients (energy, micronutrients, essential amino acids and DHA) in [(m)/(micro)gram/day] or [mg/day or mg/kg/day] | 24 weeks | |
Primary | Product acceptability | Product acceptability questionnaire [category/score] [0-10] and [0-5] | 24 weeks | |
Secondary | Compliance | Compliance (product consumption) using daily product intake diary [number of products used per week; per sachet of 33g] | 24 weeks | |
Secondary | Phenylalanine (Phe) levels | Dried bloodspot Phenylalanine (Phe) levels [µmol/L] | 24 weeks | |
Secondary | Blood chemistry: nutritional status | Blood chemistry: levels measured in blood: Full Fatty acid profile [For each FA Erythrocyte Membranes level (%FA)], full Amino acid profile [µmol/L], Vitamin B12 [pM], Vitamin D [ng/ml /nmol/L]; Folic acid [nM]; Selenium [µM]; Iodine [µg/L/ ng/mL]; Calcium [mg/dL]; Zinc [µmol/L]; Iron [µg/L] analyzed in blood samples by central laboratories | 24 weeks | |
Secondary | Anthropometrics: weight | Anthropometrics: Weight [kg] | 24 weeks | |
Secondary | Anthropometrics: height | Anthropometrics: Height [cm or m] | 24 weeks | |
Secondary | Anthropometrics: BMI | Anthropometrics: BMI [kg/m2], calculated from weight/height | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05998109 -
PheCheck Feasibility Study
|
||
Not yet recruiting |
NCT04433728 -
Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
|
||
Completed |
NCT01209819 -
Bone Mineral Density in Adults With Hyperphenylalaninemia
|
N/A | |
Active, not recruiting |
NCT05174559 -
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
|
N/A | |
Not yet recruiting |
NCT04969809 -
Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
|
N/A | |
Recruiting |
NCT04404530 -
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
|
||
Recruiting |
NCT05827536 -
Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.
|
N/A | |
Active, not recruiting |
NCT05971563 -
Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT04368624 -
PKU Skin Stripping
|
||
Completed |
NCT04452513 -
A Prospective Clinical Study of Phenylketonuria (PKU)
|
||
Completed |
NCT05497050 -
The Effect of Nursing Empowerment Program
|
N/A | |
Completed |
NCT04943393 -
Remote Neurocognitive and Psychological Assessment in PKU
|
||
Completed |
NCT05096988 -
Evaluation of PKU Sphere Liquid
|
N/A | |
Completed |
NCT00225615 -
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
|
Phase 3 | |
Recruiting |
NCT05128149 -
Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
|
||
Terminated |
NCT05229549 -
Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria
|
N/A | |
Enrolling by invitation |
NCT05356377 -
Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
|
||
Not yet recruiting |
NCT06332807 -
AAV Gene Therapy Clinical Study in Adult Classic PKU
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06337864 -
Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria
|
N/A |